Vaccines for visceral leishmaniasis: A review
K Jain, NK Jain - Journal of immunological methods, 2015 - Elsevier
Visceral leishmaniasis, which is also known as Kala-Azar, is one of the most severely
neglected tropical diseases recognized by the World Health Organization (WHO). The threat …
neglected tropical diseases recognized by the World Health Organization (WHO). The threat …
Vaccines to prevent leishmaniasis
R Kumar, C Engwerda - Clinical & translational immunology, 2014 - Wiley Online Library
Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …
affecting people in tropical and subtropical regions of the world. Epidemiological and …
Chemotherapeutics of visceral leishmaniasis: present and future developments
Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging
with few treatment options. Long duration of treatment and drug toxicity further limit the target …
with few treatment options. Long duration of treatment and drug toxicity further limit the target …
Recent developments and future prospects in the treatment of visceral leishmaniasis
Limited therapeutic options in visceral leishmaniasis (VL) make the treatment of this
neglected disease very challenging. In addition to this, long treatment duration and toxic …
neglected disease very challenging. In addition to this, long treatment duration and toxic …
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH‐F3+ GLA‐SE
RN Coler, MS Duthie, KA Hofmeyer… - Clinical & …, 2015 - Wiley Online Library
Key antigens of Leishmania species identified in the context of host responses in
Leishmania‐exposed individuals from disease‐endemic areas were prioritized for the …
Leishmania‐exposed individuals from disease‐endemic areas were prioritized for the …
Vaccine candidates for leishmaniasis: a review
R Nagill, S Kaur - International immunopharmacology, 2011 - Elsevier
Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the
genus Leishmania. The clinical manifestation of the disease varies from self-limiting …
genus Leishmania. The clinical manifestation of the disease varies from self-limiting …
Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4+ T Cells
RN Coler, Y Goto, L Bogatzki, V Raman… - Infection and …, 2007 - Am Soc Microbiol
The Leishmania-derived recombinant polyprotein Leish-111f or its three component
proteins, thiol-specific antioxidant (TSA), Leishmania major stress-inducible protein 1 …
proteins, thiol-specific antioxidant (TSA), Leishmania major stress-inducible protein 1 …
[HTML][HTML] Vaccination in leishmaniasis: a review article
L Abdellahi, F Iraji, A Mahmoudabadi… - Iranian Biomedical …, 2022 - ncbi.nlm.nih.gov
Leishmaniasis is caused by protozoan Leishmania parasites that are transmitted through
female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics …
female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics …
Case study for a vaccine against leishmaniasis
Leishmaniasis in many ways offers a unique vaccine case study. Two reasons for this are
that leishmaniasis is a disease complex caused by several different species of parasite that …
that leishmaniasis is a disease complex caused by several different species of parasite that …
The development and clinical evaluation of second-generation leishmaniasis vaccines
MS Duthie, VS Raman, FM Piazza, SG Reed - Vaccine, 2012 - Elsevier
Infection with Leishmania parasites results in a range of clinical manifestations and
outcomes. Control of Leishmania parasite transmission is extremely difficult due to the large …
outcomes. Control of Leishmania parasite transmission is extremely difficult due to the large …